1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Hutchinson Gilford Progeria Syndrome in 1 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Park, JT | 1 |
Kang, HT | 1 |
Park, CH | 1 |
Lee, YS | 1 |
Cho, KA | 1 |
Park, SC | 1 |
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hutchinson Gilford Progeria Syndrome
Article | Year |
---|---|
A crucial role of ROCK for alleviation of senescence-associated phenotype.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cell Proliferation; Cellular Senesce | 2018 |